|
Adequate Agency Funding is Critical to Cutting-Edge Biotechnology Advancement
Adequate funding for key government agencies such as the Patent and Trademark Office (PTO), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) is inextricably linked to sustained advancement in cutting edge biotechnologies. Funding of these agencies is necessary for continued research and development of life-saving therapeutics, as well as for capital formation for the biotechnology industry. Potential investors need to know that biotech products will receive a timely and high quality review. Without this assurance investors would be reluctant to invest and research and development could be hampered.
FY2005 Appropriations
A Summary of Fiscal Year 2005 Appropriations for Biotechnology-Related Federal Agencies (December 8, 2004)
Read the Summary
Agency Appropriations Archive
Older materials on this subject are available in our archive.
Browse the Archive
| 
